![]() |
市場調查報告書
商品編碼
1642689
2025-2033 年糞便隱匿測試市場報告(按測試類型、最終用戶和地區分類)Fecal Occult Testing Market Report by Test Type, End User, and Region 2025-2033 |
2024年,全球糞便隱匿檢測市場規模達14.269IMARC Group美元。大腸直腸癌盛行率的上升、非侵入性檢測技術的顯著進步、意識和篩檢計劃的提高、政府對早期癌症檢測和預防的舉措不斷增加以及人口老化是推動市場成長的一些主要因素。
糞便潛血檢查 (FOBT) 是一種非侵入性程序,用於檢測糞便或糞便中隱藏的血液。它是透過使用卡片和可沖洗試劑墊或紙巾收集樣本來執行的。這些樣本被送到實驗室進行檢測,用於診斷痔瘡、憩室病、潰瘍、結腸炎、良性腫瘤和結腸息肉或癌症等導致消化道出血的疾病。目前,人們對早期篩檢的認知不斷增強,正在推動糞便隱匿性檢測的採用,因為它可以快速做出醫療決策,提供有效的醫療保健,並提高生活品質並降低死亡率。
人們越來越關注改善患者體驗和健康結果的全面醫療服務,再加上人們越來越傾向於床邊診斷 (POCD),這是刺激市場成長的關鍵因素之一。除此之外,隨著感染疾病的風險隨著年齡的成長而增加,老年人口的增加正在加速市場的成長。因此,各國管理機構正在實施多項針對老年人的 FOBT 篩檢計畫。此外,微創(MI)手術的廣泛採用也促進了市場的成長。除此之外,免疫化學糞便潛血檢查(iFOBT 或 FIT)越來越受到關注,因為它們易於使用,並且在臨床上對癌症和晚期腺瘤更敏感。 FOBT 設備在線上零售商店的便利供應預計將對未來幾年的市場成長產生正面影響。
癒創木脂 FOB 糞便測試
免疫 FOB 凝集試驗
側流免疫 FOB 測試
免疫 FOB ELISA 測試
醫院
臨床診斷實驗室
醫師辦公室實驗室
北美洲
美國
加拿大
亞太
中國
日本
印度
韓國
澳洲
印尼
其他
歐洲
德國
法國
英國
義大利
西班牙
俄羅斯
其他
拉丁美洲
巴西
墨西哥
其他
中東和非洲
也審查了該行業的競爭格局以及主要參與者的概況,包括 Abbott Laboratories、Beckman Coulter Inc.(Danaher Corporation)、Biohit Oyj、EDP Biotech Corporation、Eiken Chemical Co. Ltd.、Epigenomics AG、Quest Diagnostics Quidel Corporation 和Randox Laboratories Ltd. 成立
The global fecal occult testing market size reached USD 1,426.9 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 2,142.2 Million by 2033, exhibiting a growth rate (CAGR) of 4.15% during 2025-2033. The rising prevalence of colorectal cancer, significant advancements in non-invasive testing technologies, increasing awareness and screening programs, growing government initiatives for early cancer detection and prevention, and rising aging populations are some of the major factors propelling the market growth.
A fecal occult blood test (FOBT) is a noninvasive procedure used to detect hidden blood in the feces or stool. It is performed by collecting samples using cards and flushable reagent pads or tissues. These samples are sent to the laboratory for testing and are used to diagnose conditions such as hemorrhoids, diverticulosis, ulcers, colitis, benign tumors and colon polyps or cancer, which cause bleeding in the digestive tract. At present, the growing awareness about early screening is promoting the adoption of fecal occult testing, as it enables quick medical decisions, provides effective healthcare, and leads to improved quality of life and the reduced mortality rate.
The rising focus on integrated health services for improved patient experience and health outcomes, in confluence with the increasing inclination towards point-of-care diagnostics (POCD), represents one of the key factors stimulating the market growth. Apart from this, the rising geriatric population is accelerating the growth of the market as the risk of contracting diseases increases with age. As a result, governing agencies of various countries are implementing several FOBT screening programs for older adults. Furthermore, the widespread adoption of minimally invasive (MI) procedures is contributing to the growth of the market. Besides this, immunochemical fecal occult blood tests (iFOBTs or FITs) are gaining traction as they are easy to use and clinically more sensitive to cancers and advanced adenomas. The easy availability of FOBT devices at online retail stores is anticipated to create a positive impact on the market growth in the upcoming years.
Guaiac FOB Stool Test
Immuno-FOB Agglutination Test
Lateral Flow Immuno-FOB Test
Immuno-FOB ELISA Test
Hospitals
Clinical Diagnostic Laboratories
Physician Office Laboratories
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Beckman Coulter Inc. (Danaher Corporation), Biohit Oyj, EDP Biotech Corporation, Eiken Chemical Co. Ltd., Epigenomics AG, Quest Diagnostics Incorporated, Quidel Corporation and Randox Laboratories Ltd.